

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT																
NATURE OF CONVEYANCE:	SECURITY AGREEMENT																
CONVEYING PARTY DATA																	
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Advanced Cell Technology, Inc.</td> <td>12/31/2012</td> </tr> <tr> <td>Mytogen, Inc.</td> <td>12/31/2012</td> </tr> </tbody> </table>		Name	Execution Date	Advanced Cell Technology, Inc.	12/31/2012	Mytogen, Inc.	12/31/2012										
Name	Execution Date																
Advanced Cell Technology, Inc.	12/31/2012																
Mytogen, Inc.	12/31/2012																
RECEIVING PARTY DATA																	
<table border="1"> <tr> <td>Name:</td> <td>CAMOFI Master LDC</td> </tr> <tr> <td>Street Address:</td> <td>c/o Centre Court Asset Management, LLC, 11 East 44th Street</td> </tr> <tr> <td>Internal Address:</td> <td>Suite 1600</td> </tr> <tr> <td>City:</td> <td>New York</td> </tr> <tr> <td>State/Country:</td> <td>NEW YORK</td> </tr> <tr> <td>Postal Code:</td> <td>10017</td> </tr> </table>		Name:	CAMOFI Master LDC	Street Address:	c/o Centre Court Asset Management, LLC, 11 East 44th Street	Internal Address:	Suite 1600	City:	New York	State/Country:	NEW YORK	Postal Code:	10017				
Name:	CAMOFI Master LDC																
Street Address:	c/o Centre Court Asset Management, LLC, 11 East 44th Street																
Internal Address:	Suite 1600																
City:	New York																
State/Country:	NEW YORK																
Postal Code:	10017																
<table border="1"> <tr> <td>Name:</td> <td>CAMHZN Master LDC</td> </tr> <tr> <td>Street Address:</td> <td>c/o Centre Court Asset Management, LLC, 11 East 44th Street</td> </tr> <tr> <td>Internal Address:</td> <td>Suite 1600</td> </tr> <tr> <td>City:</td> <td>New York</td> </tr> <tr> <td>State/Country:</td> <td>NEW YORK</td> </tr> <tr> <td>Postal Code:</td> <td>10017</td> </tr> </table>		Name:	CAMHZN Master LDC	Street Address:	c/o Centre Court Asset Management, LLC, 11 East 44th Street	Internal Address:	Suite 1600	City:	New York	State/Country:	NEW YORK	Postal Code:	10017				
Name:	CAMHZN Master LDC																
Street Address:	c/o Centre Court Asset Management, LLC, 11 East 44th Street																
Internal Address:	Suite 1600																
City:	New York																
State/Country:	NEW YORK																
Postal Code:	10017																
PROPERTY NUMBERS Total: 60																	
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>13510426</td> </tr> <tr> <td>Patent Number:</td> <td>7893315</td> </tr> <tr> <td>Patent Number:</td> <td>7838727</td> </tr> <tr> <td>Application Number:</td> <td>13004260</td> </tr> <tr> <td>Application Number:</td> <td>12905839</td> </tr> <tr> <td>Application Number:</td> <td>13585380</td> </tr> <tr> <td>Application Number:</td> <td>11989988</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	13510426	Patent Number:	7893315	Patent Number:	7838727	Application Number:	13004260	Application Number:	12905839	Application Number:	13585380	Application Number:	11989988
Property Type	Number																
Application Number:	13510426																
Patent Number:	7893315																
Patent Number:	7838727																
Application Number:	13004260																
Application Number:	12905839																
Application Number:	13585380																
Application Number:	11989988																

OP \$2400.00 13510426

Application Number:	12856043
Patent Number:	7736896
Application Number:	12781929
Application Number:	12322612
Application Number:	13721618
Application Number:	13617988
Application Number:	11842074
Application Number:	13691568
Application Number:	13653094
Application Number:	13432316
Patent Number:	6908704
Application Number:	13109666
Application Number:	13336755
Patent Number:	7621606
Application Number:	13447439
Patent Number:	7794704
Patent Number:	7795025
Patent Number:	8268303
Application Number:	12857866
Application Number:	13477763
Patent Number:	7696404
Application Number:	12528212
Patent Number:	6496720
Patent Number:	6077710
Patent Number:	6680199
Application Number:	12682712
Application Number:	12809704
Application Number:	13006064
Application Number:	13587316
Application Number:	61732144
Application Number:	13691349
Application Number:	12700545
Application Number:	12787175
Application Number:	61589741
Application Number:	61724047

	13676999
Application Number:	61638845
Application Number:	13587332
Application Number:	61740699
Application Number:	13441617
Patent Number:	8017383
Application Number:	13190988
Application Number:	12991096
Application Number:	12991111
Application Number:	12152779
Patent Number:	7910369
Application Number:	13172027
Application Number:	11430693
Application Number:	10105035
Patent Number:	6673604
Application Number:	11394637
Patent Number:	6110459
Patent Number:	6432711

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 212-813-1600

Email: tbenschar@creativity-law.com

Correspondent Name: Tal Benschar

Address Line 1: 75 Rockefeller Plaza, 19th Floor

Address Line 2: Kalow & Springut

Address Line 4: New York, NEW YORK 10019

ATTORNEY DOCKET NUMBER:

CAMOFI

NAME OF SUBMITTER:

Tal Benschar

Total Attachments: 12

source=SDOC0001#page1.tif

source=SDOC0001#page2.tif

source=SDOC0001#page3.tif

source=SDOC0001#page4.tif

source=SDOC0001#page5.tif

source=SDOC0001#page6.tif

source=SDOC0001#page7.tif

source=SDOC0001#page8.tif

PATENT
REEL: 029698 FRAME: 0003

source=SDOC0001#page9.tif
source=SDOC0001#page10.tif
source=SDOC0001#page11.tif
source=SDOC0001#page12.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of December 31, 2012 (this "Agreement"), is among Advanced Cell Technology, Inc., a Delaware corporation (the "Company"), all of the Subsidiaries of the Company signatory hereto (together with the Company, the "Debtors") and the holders of the Company's Amortizing Senior Secured Convertible Debentures due June 30, 2015 in the original aggregate principal amount of \$6,000,000 in favor of CAMOFI Master LDC ("CAMOFI") and CAMHZN Master LDC ("CAMHZN") in principal amounts of \$4,732,781 for CAMOFI and \$1,267,219 for CAMHZN, respectively (collectively, the "Debentures"), their endorsees, transferees and assigns (collectively, the "Secured Parties").

WITNESSETH:

WHEREAS, pursuant to the Settlement Agreement, dated as of December 31, 2012 (the "Settlement Agreement"), the Secured Parties have been issued the Debentures;

WHEREAS, in order to induce the Secured Parties to accept the Debentures as part of the Settlement Agreement, each Debtor has agreed to execute and deliver to the Secured Parties this Agreement and to grant the Secured Parties a security interest in certain property of such Debtor to secure the prompt payment, performance and discharge in full of all of the Company's obligations under the Debentures; and

WHEREAS, the rights of the Secured Parties hereunder shall be *pari passu* with each other Secured Party and enforced through the agent for the Secured Parties appointed pursuant to the Security Agreement (as defined below).

NOW, THEREFORE, in consideration of the agreements herein contained and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows:

1. **Certain Definitions.** Capitalized terms used herein without definition shall have the meaning assigned to those terms as defined in the Security Agreement (the "Security Agreement") dated as of even date herewith among the Company, the Debtors and the Holders.

2. **Grant of Security Interest in Collateral.** As an inducement for the Secured Parties to accept the Debentures as part of the Settlement Agreement and to secure the complete and timely payment, performance and discharge in full, as the case may be, of all of the Obligations, each Debtor hereby unconditionally and irrevocably pledges, grants and hypothecates to the Secured Parties a security interest in and to, a lien upon and a right of set-off against all of their respective right, title and interest of, priorities and privileges of whatsoever kind and nature in and to, whether under United States, multinational or foreign laws or otherwise, the following Collateral whether now owned, hereafter acquired or arising and wherever located (the "Intellectual Property Collateral");

(a) all copyrights arising under the laws of the United States, any other country or any political subdivision thereof, whether registered or unregistered and whether published or unpublished, all registrations and recordings thereof, and all applications in connection therewith, including, without limitation, all registrations, recordings and applications in the United States Copyright Office;

(b) all letters patent of the United States, any other country or any political subdivision thereof, all reissues and extensions thereof, and all applications for letters patent of

the United States or any other country and all divisions, continuations and continuations-in-part thereof;

(c) all trademarks, trade names, corporate names, company names, business names, fictitious business names, trade dress, service marks, logos, domain names and other source or business identifiers, and all goodwill associated therewith, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and all applications in connection therewith, whether in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof, or otherwise, and all common law rights related thereto;

(d) all trade secrets arising under the laws of the United States, any other country or any political subdivision thereof;

(e) all rights to obtain any reissues, renewals or extensions of the foregoing;

(f) all licenses for any of the foregoing; and

(g) all causes of action for infringement of the foregoing.

Notwithstanding the foregoing, the term "Intellectual Property Collateral" shall not include:

(1) any asset, the granting of a security interest in which would be void or illegal under any applicable law, rule or regulation of any governmental authority, or pursuant thereto would result in, or permit the termination of, such asset;

(2) any property of any Debtor to the extent that the Secured Parties shall determine in their sole discretion that the costs of obtaining a security interest in such property is excessive in relation to the value of the security to be afforded thereby; and

(3) United States intent-to-use trademark applications to the extent that, and solely during the period in which, the grant of a security interest therein would impair the validity or enforceability of such intent-to-use trademark applications under applicable federal law;

provided that the limitation set forth in clause (1) above shall (x) exist only for so long as such law, rule, regulation, general intangibles, contracts, or other rights arising under any contracts, instruments, or other documents, continue to be effective (and, upon the cessation, termination, expiration of such law, rule, regulation, general intangibles, contracts, or other rights arising under any contracts, instruments, or other documents, or if any such law, rule, regulation, general intangibles, contracts, or other rights arising under any contracts, instruments, or other documents is no longer applicable, the security interest granted herein shall be deemed to have automatically attached to such asset) and (y) not apply with respect to any asset if and to the extent that the security interest in and to such asset granted pursuant to this Agreement is permitted under Sections 9-406, 9-407, 9-408, or 9-409 of the UCC.

3. **Security for the Obligation.** This Intellectual Property Security Agreement and the security interests created hereby secure the payment and performance of the Obligations, whether now existing or arising hereafter. Without limiting the generality of the foregoing, this Intellectual Property Security Agreement secures the payment of all amounts which constitute part of the Obligations and would be owed by Debtors, or any of them, to Agent or the Holders, whether or not they are unenforceable or not allowable due to the existence of a bankruptcy or an insolvency proceeding involving any Debtor.

4. **Settlement Agreement & Security Agreement.** The security interest granted pursuant to this Intellectual Property Security Agreement is granted in conjunction with, and in no way limiting, the security interest granted to the Agent and Holders pursuant to the Security Agreement, and each Debtor hereby acknowledges and agrees that the rights and remedies of the Agent with respect to the security interest in the Intellectual Property Collateral made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein

5. **Authorization to Supplement.** If any Debtor shall obtain rights to any new patentable inventions or become entitled to the benefit of any patent application or patent for any reissue, division, or continuation, of any patent, the provisions of this Intellectual Property Security Agreement shall automatically apply thereto. Debtors shall give prompt (and in any event within fifteen (15) Business Days) notice in writing to Agent with respect to any such new patent rights. Without limiting Debtors' obligations under this Section 5, Debtors hereby authorize Agent on behalf of the Secured Parties unilaterally to modify this Agreement by amending Schedule I to include any such new patent rights of Debtors. Notwithstanding the foregoing, no failure to so modify this Intellectual Property Security Agreement or amend Schedule I shall in any way affect, invalidate or detract from Agent's and the Secured Parties' continuing Security Interest in all Collateral, whether or not listed on Schedule I.

6. **Miscellaneous.**

(a) No course of dealing between the Debtors and the Secured Parties, nor any failure to exercise, nor any delay in exercising, on the part of the Secured Parties, any right, power or privilege hereunder or under the Debentures shall operate as a waiver thereof; nor shall any single or partial exercise of any right, power or privilege hereunder or thereunder preclude any other or further exercise thereof or the exercise of any other right, power or privilege.

(b) If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

(c) No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.

(d) This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. Debtors may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Secured Party (other than by merger). Any Secured Party may assign any or all of its rights under this Agreement to any Person to whom such Secured Party assigns or transfers any Securities, provided such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of this Agreement that apply to the "Secured Parties."

(e) Each party shall take such further action and execute and deliver such further documents as may be necessary or appropriate in order to carry out the provisions and purposes of this Agreement.

(f) All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each Debtor agrees that all proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and the Debentures (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York, Borough of Manhattan. Each Debtor hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such proceeding is improper. Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Each party hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. If any party shall commence a proceeding to enforce any provisions of this Agreement, then the prevailing party in such proceeding shall be reimbursed by the other party for its reasonable attorney's fees and other costs and expenses incurred with the investigation, preparation and prosecution of such proceeding.

(g) This Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and, all of which taken together shall constitute one and the same Agreement. In the event that any signature is delivered by facsimile transmission, such signature shall create a valid binding obligation of the party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile signature were the original thereof.


(h) Upon the payment in full of the Obligations, the security interests granted hereunder shall automatically terminate and be released and the Debtors may file evidence of such termination on behalf of the Secured Parties. Notwithstanding the foregoing, upon payment in full of the Obligations, Secured Parties shall execute, acknowledge and deliver to the Debtors on such day of payment an instrument in writing provided by Debtors in form and substance satisfactory to Secured Parties in recordable form terminating the collateral pledge, grant, assignment, lien and security interest in the IP Collateral under this Agreement.

[SIGNATURE PAGES FOLLOW]


IN WITNESS WHEREOF, the parties hereto have caused this Intellectual Property Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

DEBTORS:

ADVANCED CELL TECHNOLOGY, INC.

By: 
Name: Gary Rubin
Title: CEO

MYTOGEN, INC.

By: 
Name: Gary Rubin
Title: CEO

ACCEPTED AND AGREED
as of the date first above written:

CAMOFT Master LDC, As Agent

By: _____
Name:
Title:

[INTELLECTUAL PROPERTY SECURITY AGREEMENT SIGNATURE PAGE]

IN WITNESS WHEREOF, the parties hereto have caused this Intellectual Property Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

DEBTORS:

ADVANCED CELL TECHNOLOGY, INC.

By: _____
Name:
Title:

MYTOGEN, INC.

By: _____
Name:
Title:

ACCEPTED AND AGREED
as of the date first above written:

CAMOFI Master LDC, As Agent

By: Richard Smith
Name: Richard Smith
Title: Agent

[INTELLECTUAL PROPERTY SECURITY AGREEMENT SIGNATURE PAGE]

Schedule I Intellectual Property

Attorney Docket No.	Country Name	Application Number	Title	Application's Status	Patent No.
75820-001030	United States of America	13/510426	METHODS OF PRODUCING HUMAN RPE CELLS AND PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS	Pending	
75820-001050	Canada	2731149	METHODS OF PRODUCING HUMAN RPE CELLS AND PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS	Pending	
75820-001070	European Patent Convention	10832114.2	METHODS OF PRODUCING HUMAN RPE CELLS AND PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS	Published	
75820-001080	Israel	219787	METHODS OF PRODUCING HUMAN RPE CELLS AND PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS	Pending	
75820-003010	United States of America	11/800366	DERIVATION OF EMBRYONIC STEM CELLS AND EMBRYONIC-DERIVED CELLS	Granted	7893315
75820-003011	United States of America	11/267555	DERIVATION OF EMBRYONIC STEM CELLS	Granted	7938727
75820-003012	United States of America	13/004260	DERIVATION OF EMBRYONIC STEM CELLS AND EMBRYO-DERIVED CELLS	Published	
75820-003013	United States of America	12/905899	DERIVATION OF EMBRYONIC STEM CELLS	Published	
75820-003031	Australia	2007248412	DERIVATION OF EMBRYONIC STEM CELLS AND EMBRYO-DERIVED CELLS	Pending	
75820-003062	Australia	2012200623	DERIVATION OF EMBRYONIC STEM CELLS	Pending	
75820-003060	Canada	2688098	DERIVATION OF EMBRYONIC STEM CELLS	Pending	
75820-003070	European Patent Convention	5819524.9	DERIVATION OF EMBRYONIC STEM CELLS	Published	
75820-003071	European Patent Convention	7794602.8	DERIVATION OF EMBRYONIC STEM CELLS AND EMBRYO-DERIVED CELLS	Published	
75820-003072	European Patent Convention	11000561.9	DERIVATION OF EMBRYONIC STEM CELLS	Published	
75820-003073	European Patent Convention	12197502.3	DERIVATION OF EMBRYONIC STEM CELLS	Pending	
75820-003090	Japan	2007-540021	DERIVATION OF EMBRYONIC STEM CELLS	Published	
75820-003091	Japan	2012-225193	DERIVATION OF EMBRYONIC STEM CELLS	Pending	
75820-003111	New Zealand	596597	DERIVATION OF EMBRYONIC STEM CELLS	Pending	
75820-003112	New Zealand	599613	DERIVATION OF EMBRYONIC STEM CELLS	Pending	
75820-004012	United States of America	13/585380	TOTIPOTENT, NEARLY TOTIPOTENT OR PLURIPOTENT MAMMALIAN CELLS HOMOZYGOUS OR HEMIZYGOUS FOR ONE OR MORE HISTOCOMPATIBILITY ANTIGEN GENES	Pending	
75820-005010	United States of America	11/989988	METHODS OF REPROGRAMMING ANIMAL SOMATIC CELLS	Published	
75820-005013	United States of America	12/956043	METHODS OF REPROGRAMMING ANIMAL SOMATIC CELLS	Published	
75820-006010	United States of America	11/186720	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Granted	7736896
75820-006011	United States of America	12/781929	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Published	
75820-006030	Australia	2005325753	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Granted	2005325753
75820-006031	Australia	2012201562	IMPROVED MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Pending	
75820-006050	Canada	2696227	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Pending	
75820-006070	European Patent Convention	5773674.6	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Published	
75820-006071	European Patent Convention	12159755.3	IMPROVED MODALITIES MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Published	
75820-006090	Japan	2007-552111	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Published	
75820-006091	Japan	2011-209002	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Published	
75820-010012	United States of America	12/322612	SCREENING ASSAYS FOR IDENTIFYING DIFFERENTIATION-INDUCING AGENTS AND PRODUCTION OF DIFFERENTIATED CELLS FOR CELL THERAPY	Published	
75820-010032	Australia	2012205203	SCREENING ASSAYS FOR IDENTIFYING DIFFERENTIATION-INDUCING AGENTS AND PRODUCTION OF DIFFERENTIATED CELLS FOR CELL THERAPY	Pending	
75820-010063	Canada	2458575	SCREENING ASSAYS FOR IDENTIFYING DIFFERENTIATION-INDUCING AGENTS AND PRODUCTION OF DIFFERENTIATED CELLS FOR CELL THERAPY	Pending	

75820-010080	Israel	160507	MESODERMAL LINEAGE CELLS AND METHOD OF DERIVATION OF SAME	Granted	160507
75820-010081	Israel	214969	SCREENING ASSAYS FOR IDENTIFYING DIFFERENTIATION-INDUCING AGENTS AND PRODUCTION OF DIFFERENTIATED CELLS FOR CELL THERAPY	Pending	
75820-010082	Israel	214970	SCREENING ASSAYS FOR IDENTIFYING DIFFERENTIATION-INDUCING AGENTS AND PRODUCTION OF DIFFERENTIATED CELLS FOR CELL THERAPY	Pending	
75820-010100	Mexico	PA/02004/001725	SCREENING ASSAYS FOR IDENTIFYING DIFFERENTIATION-INDUCING AGENTS AND PRODUCTION OF DIFFERENTIATED CELLS FOR CELL THERAPY	Pending	
75820-011011	United States of America	13/721618	BANK OF STEM CELLS FOR PRODUCING CELLS FOR TRANSPLANTATION HAVING HLA ANTIGENS MATCHING THOSE OF TRANSPLANT RECIPIENTS, AND METHODS FOR MAKING AND USING SUCH A STEM CELL BANK	Pending	
75820-011050	Canada	2505598	BANK OF STEM CELLS FOR PRODUCING CELLS FOR TRANSPLANTATION HAVING HLA ANTIGENS MATCHING THOSE OF TRANSPLANT RECIPIENTS, AND METHODS FOR MAKING AND USING SUCH A STEM CELL BANK	Pending	
75820-011070	European Patent Convention	3736723.2	BANK OF STEM CELLS FOR PRODUCING CELLS FOR TRANSPLANTATION HAVING HLA ANTIGENS MATCHING THOSE OF TRANSPLANT RECIPIENTS, AND METHODS FOR MAKING AND USING SUCH A STEM CELL BANK	Published	
75820-014014	United States of America	13/617388	CYTOPLASMIC TRANSFER TO DE-DIFFERENTIATE RECIPIENT CELLS	Pending	
75820-014050	Canada	2377515	CYTOPLASMIC TRANSFER TO DE-DIFFERENTIATE RECIPIENT CELLS	Pending	
75820-014080	Israel	147179	CYTOPLASMIC TRANSFER TO DE-DIFFERENTIATE RECIPIENT CELLS	Pending	
75820-014110	New Zealand	516236	CYTOPLASMIC TRANSFER TO DE-DIFFERENTIATE RECIPIENT CELLS	Granted	516236
75820-015013	United States of America	11/842074	DE-DIFFERENTIATION AND RE-DIFFERENTIATION OF SOMATIC CELLS AND PRODUCTION OF CELL FOR CELL THERAPIES	Published	
75820-016012	United States of America	13/691568	GENERATION OF HISTOCOMPATIBLE TISSUES USING NUCLEAR TRANSPLANTATION	Pending	
75820-016051	Canada	2505592	GENERATION OF HISTOCOMPATIBLE TISSUES USING NUCLEAR TRANSPLANTATION	Pending	
75820-017012	United States of America	13/663094	METHODS FOR MAKING AND USING REPROGRAMMED HUMAN SOMATIC CELL NUCLEI AND AUTOLOGOUS AND ISOGENIC HUMAN STEM CELLS	Pending	
75820-018030	Australia	2002322522	METHODS AND COMPOSITIONS FOR CELL THERAPY	Granted	2002322522
75820-018031	Australia	2010201668	METHODS AND COMPOSITIONS FOR CELL THERAPY	Pending	
75820-020012	United States of America	13/432316	METHOD FOR FACILITATING THE PRODUCTION OF DIFFERENTIATED CELL TYPES AND TISSUES FROM EMBRYONIC AND ADULT PLURIPOTENT AND MULTIPOTENT CELLS	Pending	
75820-021010	United States of America	09/655815	METHOD FOR GENERATING IMMUNE-COMPATIBLE CELLS AND TISSUES USING NUCLEAR TRANSFER TECHNIQUES	Granted	6808704
75820-021013	United States of America	13/108666	METHOD FOR GENERATING IMMUNE-COMPATIBLE CELLS AND TISSUES USING NUCLEAR TRANSFER TECHNIQUES	Published	
75820-021032	Australia	76755/00	METHOD FOR GENERATING IMMUNE-COMPATIBLE CELLS AND TISSUES USING NUCLEAR TRANSFER TECHNIQUES	Granted	793162
75820-021080	Israel	148418	METHOD FOR GENERATING IMMUNE-COMPATIBLE CELLS AND TISSUES USING NUCLEAR TRANSFER TECHNIQUES	Pending	
75820-021100	Mexico	PA/02002/002444	METHOD FOR GENERATING IMMUNE-COMPATIBLE CELLS AND TISSUES USING NUCLEAR TRANSFER TECHNIQUES	Granted	255679
75820-021110	New Zealand	536786	METHOD FOR GENERATING IMMUNE-COMPATIBLE CELLS AND TISSUES USING NUCLEAR TRANSFER TECHNIQUES	Granted	536786
75820-026016	United States of America	13/336755	METHODS OF REPAIRING TANDEMLY REPEATED DNA SEQUENCES AND EXTENDING CELL LIFE-SPAN USING NUCLEAR TRANSFER	Published	
75820-026050	Canada	2583790	TELOMERE RESTORATION AND EXTENSION OF CELL LIFE-SPAN IN ANIMALS CLONED FROM SENESECENT SOMATIC CELLS	Pending	
75820-026080	Israel	148457	TELOMERE RESTORATION AND EXTENSION OF CELL LIFE-SPAN IN ANIMALS CLONED FROM SENESECENT SOMATIC CELLS	Pending	
75820-026111	New Zealand	531844	METHODS OF RESTORING TANDEMLY REPEATED DNA SEQUENCES AND EXTENDING CELL LIFE-SPAN USING NUCLEAR TRANSFER	Granted	531844
75820-036010	United States of America	10/228296	TRANS-DIFFERENTIATION AND RE-DIFFERENTIATION OF SOMATIC CELLS AND PRODUCTION OF CELLS FOR CELL THERAPIES	Granted	7521606
75820-038012	United States of America	13/447439	USE OF RNA INTERFERENCE FOR THE CREATION OF LINEAGE SPECIFIC ES AND OTHER UNDIFFERENTIATED CELLS AND PRODUCTION OF DIFFERENTIATED CELLS IN VITRO BY CO-CULTURE	Pending	
75820-040010	United States of America	11/041382	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Granted	7794704
75820-040011	United States of America	11/450953	METHODS FOR PRODUCING ENRICHED POPULATIONS OF HUMAN RETINAL PIGMENT EPITHELIUM CELLS	Granted	7795025
75820-040012	United States of America	12/857911	METHODS FOR PRODUCING ENRICHED POPULATIONS OF HUMAN RETINAL PIGMENT EPITHELIUM CELLS FOR TREATMENT OF RETINAL DEGENERATION	Granted	8268303
75820-040013	United States of America	12/857966	METHODS FOR PRODUCING ENRICHED POPULATIONS OF HUMAN RETINAL PIGMENT EPITHELIUM CELLS	Published	
75820-040014	United States of America	13/477763	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Pending	

75820 - 040030	Australia	2005207042	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Granted	2005207042
75820 - 040031	Australia	2010249263	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Pending	
75820 - 040050	Canada	2555370	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Pending	
75820 - 040060	China (People's Republic)	200580007359.0	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Granted	ZL200580007359.0
75820 - 040061	China (People's Republic)	201110132307.3	IMPROVED MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Published	
75820 - 040070	European Patent Convention	5711960.4	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Published	
75820 - 040071	European Patent Convention	11183610.2	DN1/IMPROVED MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Published	
75820 - 040072	European Patent Convention	11183613.6	DN2/IMPROVED MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Published	
75820 - 040073	European Patent Convention	11183611	DN3/IMPROVED MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Published	
75820 - 040073-HK	Hong Kong	12109821.2	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Published	
75820 - 040080	Israel	177015	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Pending	
75820 - 040091	Japan	2012-040491	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Pending	
75820 - 040100	Mexico	PA/a/2005/008299	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Granted	287357
75820 - 040101	Mexico	MX/a/2011/006096	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Pending	
75820 - 040110	New Zealand	548929	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Granted	548929
75820 - 040131	Singapore	200905545-8	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Pending	
75820 - 040150	Hong Kong	7103629.4	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Published	
75820 - 040151	Hong Kong	12103435.3	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Published	
75820 - 040160	India	2373/KOLNP/2006	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Pending	
75820 - 040161	India	1472/KOLNP/2011	MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA	Pending	
75820 - 042010	United States of America	10/329679	EMBRYONIC OR STEM-LIKE CELL LINES PRODUCED BY CROSS SPECIES NUCLEAR TRANSPLANTATION AND METHODS FOR ENHANCING EMBRYONIC DEVELOPMENT BY GENETIC ALTERATION OF DONOR CELLS OR BY TISSUE CULTURE CONDITIONS	Granted	7696404
75820 - 066110	New Zealand	519347	METHOD TO PRODUCE CLONED EMBRYOS AND ADULTS FROM CULTURED CELLS	Granted	519347
75820 - 084010	United States of America	12/528212	HIGHLY EFFICIENT METHODS FOR REPROGRAMMING DIFFERENTIATED CELLS AND FOR GENERATING ANIMALS AND EMBRYONIC STEM CELLS FROM REPROGRAMMED CELLS	Published	
75820 - 084030	Australia	2008218998	HIGHLY EFFICIENT METHODS FOR REPROGRAMMING DIFFERENTIATED CELLS AND FOR GENERATING ANIMALS AND EMBRYONIC STEM CELLS FROM REPROGRAMMED CELLS	Pending	
75820 - 084050	Canada	2679109	HIGHLY EFFICIENT METHODS FOR REPROGRAMMING DIFFERENTIATED CELLS AND FOR GENERATING ANIMALS AND EMBRYONIC STEM CELLS FROM REPROGRAMMED CELLS	Pending	
75820 - 084060	China (People's Republic)	200880013190.3	HIGHLY EFFICIENT METHODS FOR REPROGRAMMING DIFFERENTIATED CELLS AND FOR GENERATING ANIMALS AND EMBRYONIC STEM CELLS FROM REPROGRAMMED CELLS	Published	
75820 - 084070	European Patent Convention	8725969.3	HIGHLY EFFICIENT METHODS FOR REPROGRAMMING DIFFERENTIATED CELLS AND FOR GENERATING ANIMALS AND EMBRYONIC STEM CELLS FROM REPROGRAMMED CELLS	Published	
75820 - 084080	Israel	200522	HIGHLY EFFICIENT METHODS FOR REPROGRAMMING DIFFERENTIATED CELLS AND FOR GENERATING ANIMALS AND EMBRYONIC STEM CELLS FROM REPROGRAMMED CELLS	Pending	
75820 - 084090	Japan	2009-550931	HIGHLY EFFICIENT METHODS FOR REPROGRAMMING DIFFERENTIATED CELLS AND FOR GENERATING ANIMALS AND EMBRYONIC STEM CELLS FROM REPROGRAMMED CELLS	Published	
75820 - 084120	Korea, Republic of	10-2009-7015691	HIGHLY EFFICIENT METHODS FOR REPROGRAMMING DIFFERENTIATED CELLS AND FOR GENERATING ANIMALS AND EMBRYONIC STEM CELLS FROM REPROGRAMMED CELLS	Published	
75820 - 084150	Hong Kong	10199158.7	HIGHLY EFFICIENT METHODS FOR REPROGRAMMING DIFFERENTIATED CELLS AND FOR GENERATING ANIMALS AND EMBRYONIC STEM CELLS FROM REPROGRAMMED CELLS	Published	
75820 - 100010	United States of America	08/016703	PARTHENOGENIC OOCYTE ACTIVATION	Granted	5496720
75820 - 100013	United States of America	09/176395	PARTHENOGENIC OOCYTE ACTIVATION	Granted	6077710
75820 - 105012	United States of America	09/576592	IN VITRO ACTIVATION OF MAMMALIAN OOCYTES	Granted	6680199
75820 - 120070	European Patent Convention	96907992.8	USE OF EMBRYONIC STEM CELLS AS NUCLEAR DONORS DURING NUCLEAR TRANSFER, AND USE OF SAID TECHNIQUES TO PROVIDE CHIMERIC AND TRANSGENIC ANIMALS	EPGrant	739412

75820 - 125010	United States of America	12/5682712	METHODS OF PRODUCING RPE CELLS AND COMPOSITIONS OF RPE CELLS	Published	
75820 - 125030	Australia	2008312007	METHODS OF PRODUCING RPE CELLS AND COMPOSITIONS OF RPE CELLS	Pending	
75820 - 125050	Canada	2702386	METHODS OF PRODUCING RPE CELLS AND COMPOSITIONS OF RPE CELLS	Pending	
75820 - 125060	China (People's Republic)	200890118061	METHODS OF PRODUCING RPE CELLS AND COMPOSITIONS OF RPE CELLS	Published	
75820 - 125070	European Patent Convention	9839134.7	METHODS OF PRODUCING RPE CELLS AND COMPOSITIONS OF RPE CELLS	Published	
75820 - 125080	Israel	204956	METHODS OF PRODUCING RPE CELLS AND COMPOSITIONS OF RPE CELLS	Published	
75820 - 125090	Japan	2010-528899	METHODS OF PRODUCING RPE CELLS AND COMPOSITIONS OF RPE CELLS	Pending	
75820 - 125150	Hong Kong	11104208.7	METHODS OF PRODUCING RPE CELLS AND COMPOSITIONS OF RPE CELLS	Published	
75820 - 125160	India	1547/KOLNP/2010	METHODS OF PRODUCING RPE CELLS AND COMPOSITIONS OF RPE CELLS	Pending	
75820 - 129010	United States of America	12/809704	METHODS FOR PRODUCING PLURIPOTENT STEM CELL-GENERATED EMBRYOS, AND ANIMALS DERIVED THEREFROM	Published	
75820 - 160020	Patent Cooperation Treaty	PCT/US11/45232	METHODS FOR DETECTION OF RARE SUBPOPULATIONS OF CELLS AND HIGHLY PURIFIED COMPOSITIONS OF CELLS	Published	
75820 - 170001	United States of America	13/006064	METHODS AND COMPOSITIONS FOR REPROGRAMMING CELLS	Published	
75820 - 190010	United States of America	13/587316	PLURIPOTENT STEM CELLS	Pending	
75820 - 200020	Patent Cooperation Treaty	PCT/US12/68305	METHOD OF DIRECTED DIFFERENTIATION PRODUCING CORNEAL ENDOTHELIAL CELLS, COMPOSITIONS THEREOF, AND USES THEREOF	Pending	
75820 - 210002	United States of America	61/732144	MESENCHYMAL STROMAL CELLS USES AND USES RELATED THERETO	Pending	
75820 - 210010	United States of America	13/691349	MESENCHYMAL STROMAL CELLS AND USES RELATED THERETO	Pending	
75820 - 210020	Patent Cooperation Treaty	PCT/US12/67464	MESENCHYMAL STROMAL CELLS USES AND USES RELATED THERETO	Pending	
75820 - 210140	Taiwan	N/A	METHODS OF GENERATING MESENCHYMAL STROMAL CELLS USING HEMANGIOBLASTS	Pending	
75820 - 220010	United States of America	12/700545	GENETICALLY INTACT INDUCED PLURIPOTENT CELLS OR TRANSDIFFERENTIATED CELLS AND METHODS FOR THE PRODUCTION THEREOF	Published	
75820 - 220011	United States of America	12/767175	GENETICALLY INTACT INDUCED PLURIPOTENT CELLS OR TRANSDIFFERENTIATED CELLS AND METHODS FOR THE PRODUCTION THEREOF	Published	
75820 - 220030	Australia	2010254230	GENETICALLY INTACT INDUCED PLURIPOTENT CELLS OR TRANSDIFFERENTIATED CELLS AND METHODS FOR THE PRODUCTION THEREOF	Pending	
75820 - 220055	Canada	2763618	GENETICALLY INTACT INDUCED PLURIPOTENT CELLS OR TRANSDIFFERENTIATED CELLS AND METHODS FOR THE PRODUCTION THEREOF	Pending	
75820 - 220057	European Patent Convention	10791096.2	GENETICALLY INTACT INDUCED PLURIPOTENT CELLS OR TRANSDIFFERENTIATED CELLS AND METHODS FOR THE PRODUCTION THEREOF	Published	
75820 - 220060	China (People's Republic)	201090031617.7	GENETICALLY INTACT INDUCED PLURIPOTENT CELLS OR TRANSDIFFERENTIATED CELLS AND METHODS FOR THE PRODUCTION THEREOF	Pending	
75820 - 230002	United States of America	61/589741	PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS AND USES THEREOF	Pending	
75820 - 230003	United States of America	61/724047	PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS AND USES THEREOF	Pending	
75820 - 230010	United States of America	13/676999	PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS AND USES THEREOF	Pending	
75820 - 230020	Patent Cooperation Treaty	PCT/US12/65091	PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS AND USES THEREOF	Pending	
75820 - 230140	Taiwan	101142511	PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS AND USES THEREOF	Pending	
75820 - 230207	United Kingdom	1220511.8	PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS AND USES THEREOF	Pending	
75820 - 240001	United States of America	61/639645	MEGAKARTOCYTES AND USES THEREOF	Pending	
75820 - 250010	United States of America	13/587332	CATHETER-BASED DELIVERY OF SKELETAL MYOBLASTS TO THE MYOCARDIUM OF DAMAGED HEARTS	Pending	
75820 - 260001	United States of America	61/740699	METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF	Pending	
75820 - 700200	United States of America	13/441617	LASER ISOLATION OF VIABLE CELLS	Published	
065473-999001US00	United States of America	11/767262	HEMANGIO-COLONY FORMING CELLS	Issued	8017393

06547-999001US10	United States of America	13/190988	HEMANGIO-COLONY FORMING CELLS	Published	
06547-999001AU00	Australia	2007238660	HEMANGIO-COLONY FORMING CELLS	Pending	
06547-999001EP00	European Patent Convention	7755391.5	HEMANGIO-COLONY FORMING CELLS	Published	
06547-999001EP10	European Patent Convention	11155399.6	HEMANGIO-COLONY FORMING CELLS	Published	
06547-999001EP20	European Patent Convention	11155482.0	HEMANGIO-COLONY FORMING CELLS	Published	
06547-999001EP30	European Patent Convention	11155495.2	HEMANGIO-COLONY FORMING CELLS	Pending	
06547-999001EP40	European Patent Convention	11155500.9	HEMANGIO-COLONY FORMING CELLS	Pending	
06547-999001JP00	Japan	PCT/US2007/009106	HEMANGIO-COLONY FORMING CELLS	Published	
06547-999001KR00	Korea, Republic of	10-2008-7027950	HEMANGIO-COLONY FORMING CELLS	Pending	
06547-999001NZ00	New Zealand	572842	HEMANGIO-COLONY FORMING CELLS	Granted	572842
06547-999001NZ10	New Zealand	596761	HEMANGIO-COLONY FORMING CELLS	Pending	
065473-999003US00	United States of America	12/991096	HEMANGIO COLONY FORMING CELLS AND NON-ENGRAFTING HEMANGIO CELLS	Pending	
065473-999003AU00	Australia	2009244231	HEMANGIO COLONY FORMING CELLS AND NON-ENGRAFTING HEMANGIO CELLS	Pending	
065473-999003CA00	Canada	2722693	HEMANGIO COLONY FORMING CELLS AND NON-ENGRAFTING HEMANGIO CELLS	Pending	
065473-999003CN00	China (People's Republic)	200980125860.5	HEMANGIO COLONY FORMING CELLS AND NON-ENGRAFTING HEMANGIO CELLS	Published	
065473-999003EP00	European Patent Convention	09743610.9	HEMANGIO COLONY FORMING CELLS AND NON-ENGRAFTING HEMANGIO CELLS	Published	
065473-999003HK00	Hong Kong	09743610.9	HEMANGIO COLONY FORMING CELLS AND NON-ENGRAFTING HEMANGIO CELLS	Published	
065473-999003IN00	India	4273/KOLNP/2010	HEMANGIO COLONY FORMING CELLS AND NON-ENGRAFTING HEMANGIO CELLS	Pending	
065473-999003JP00	Japan	2011-509644	HEMANGIO COLONY FORMING CELLS AND NON-ENGRAFTING HEMANGIO CELLS	Published	
065473-999003US10	United States of America	12/991111	METHODS FOR PRODUCING ENUCLEATED ERYTHROID CELLS DERIVED FROM PLURIPOTENT STEM CELLS	Published	
065473-999003AU10	Australia	2009244236	METHODS FOR PRODUCING ENUCLEATED ERYTHROID CELLS DERIVED FROM PLURIPOTENT STEM CELLS	Pending	
065473-999003BR10	Brazil	PI0912517-5	METHODS FOR PRODUCING ENUCLEATED ERYTHROID CELLS DERIVED FROM PLURIPOTENT STEM CELLS	Pending	
065473-999003CA10	Canada	2722766	METHODS FOR PRODUCING ENUCLEATED ERYTHROID CELLS DERIVED FROM PLURIPOTENT STEM CELLS	Pending	
065473-999003EP10	European Patent Convention	09743615.8	METHODS FOR PRODUCING ENUCLEATED ERYTHROID CELLS DERIVED FROM PLURIPOTENT STEM CELLS	Published	
065473-999003HK10	Hong Kong	11107912.6	METHODS FOR PRODUCING ENUCLEATED ERYTHROID CELLS DERIVED FROM PLURIPOTENT STEM CELLS	Published	
065473-999003IN10	India	4274/KOLN/2010	METHODS FOR PRODUCING ENUCLEATED ERYTHROID CELLS DERIVED FROM PLURIPOTENT STEM CELLS	Pending	
065473-999003JP10	Japan	2011-509646	METHODS FOR PRODUCING ENUCLEATED ERYTHROID CELLS DERIVED FROM PLURIPOTENT STEM CELLS	Published	
065473-999003MX10	Mexico	MX/a/2010/012099	METHODS FOR PRODUCING ENUCLEATED ERYTHROID CELLS DERIVED FROM PLURIPOTENT STEM CELLS	Pending	
BIOT-0170ON3	United States of America	12/152779	METHOD OF DIFFERENTIATION OF MORULA OR INNER CELL MASS CELLS AND METHOD OF MAKING LINEAGE-DEFECTIVE EMBRYONIC STEM CELLS	Pending	
BIOT-017AU	Australia	200112000	METHOD OF DIFFERENTIATION OF MORULA OR INNER CELL MASS CELLS AND METHOD OF MAKING LINEAGE-DEFECTIVE EMBRYONIC STEM CELLS	Granted	792385 B2
BIOT-017BR	Brazil	PI0014864-4	METHOD OF DIFFERENTIATION OF MORULA OR INNER CELL MASS CELLS AND METHOD OF MAKING LINEAGE-DEFECTIVE EMBRYONIC STEM CELLS	Pending	
BIOT-017CA	Canada	2388497	METHOD OF DIFFERENTIATION OF MORULA OR INNER CELL MASS CELLS AND METHOD OF MAKING LINEAGE-DEFECTIVE EMBRYONIC STEM CELLS	Pending	
BIOT-017CN	China (People's Republic)	30817477.5	METHOD OF DIFFERENTIATION OF MORULA OR INNER CELL MASS CELLS AND METHOD OF MAKING LINEAGE-DEFECTIVE EMBRYONIC STEM CELLS	Pending	
BIOT-017EP	European Patent Convention	00973497.1	METHOD OF DIFFERENTIATION OF MORULA OR INNER CELL MASS CELLS AND METHOD OF MAKING LINEAGE-DEFECTIVE EMBRYONIC STEM CELLS	Pending	
BIOT-017IL	Israel	149043	METHOD OF DIFFERENTIATION OF MORULA OR INNER CELL MASS CELLS AND METHOD OF MAKING LINEAGE-DEFECTIVE EMBRYONIC STEM CELLS	Published	

BIOT-017JP	Japan	2001-532190	METHOD OF DIFFERENTIATION OF MORULA OR INNER CELL MASS CELLS AND METHOD OF MAKING LINEAGE-DEFECTIVE EMBRYONIC STEM CELLS	Pending	
BIOT-017MX	Mex	PA/02002003739	METHOD OF DIFFERENTIATION OF MORULA OR INNER CELL MASS CELLS AND METHOD OF MAKING LINEAGE-DEFECTIVE EMBRYONIC STEM CELLS	Pending	
BIOT-017NZ	New Zealand	518191	METHOD OF DIFFERENTIATION OF MORULA OR INNER CELL MASS CELLS AND METHOD OF MAKING LINEAGE-DEFECTIVE EMBRYONIC STEM CELLS	Granted	518191
BIOT-016CON1	United States of America	11/211174	NOVEL CULTURE SYSTEMS FOR EX VIVO DEVELOPMENT	Granted	7910369
BIOT-016CON3	United States of America	13/172027	NOVEL CULTURE SYSTEMS FOR EX VIVO DEVELOPMENT	Published	
BIOT-016AU	Australia	2005205516	NOVEL CULTURE SYSTEMS FOR EX VIVO DEVELOPMENT	Granted	2005205516
BIOT-016CA	Canada	2552288	NOVEL CULTURE SYSTEMS FOR EX VIVO DEVELOPMENT	Pending	
BIOT-016EP	European Patent Convention	06704927.1	NOVEL CULTURE SYSTEMS FOR EX VIVO DEVELOPMENT	Published	
BIOT-016IL	Israel	176641	NOVEL CULTURE SYSTEMS FOR EX VIVO DEVELOPMENT	Granted	176641
BIOT-016NZ	New Zealand	548623	NOVEL CULTURE SYSTEMS FOR EX VIVO DEVELOPMENT	Granted	548623
19412-5001US	United States of America	11/430693	CELLULAR CARDIOMYOPLASTY AS SUPPORTIVE THERAPY IN PATIENTS WITH HEART DISEASE	Published	
19412-5003CA	Canada	2479582	MUSCLE CELLS AND THEIR USE IN CARDIAC REPAIR	Pending	
19412-5003JP02	Japan	2007-197596	MUSCLE CELLS AND THEIR USE IN CARDIAC REPAIR	Published	
19412-5003JP03	Japan	2003-678628	MUSCLE CELLS AND THEIR USE IN CARDIAC REPAIR	Published	
19412-5003JP04	Japan	2010-185658	MUSCLE CELLS AND THEIR USE IN CARDIAC REPAIR	Published	
19412-5003JP05	Japan	2011-152353	MUSCLE CELLS AND THEIR USE IN CARDIAC REPAIR	Published	
19412-5003US	United States of America	10/105035	MUSCLE CELLS AND THEIR USE IN CARDIAC REPAIR	Published	
19412-5003-US02	United States of America	95/000152	MUSCLE CELLS AND THEIR USE IN CARDIAC REPAIR	Reissue	6673604
19412-5004AU	Australia	2006244639	TREATMENT OF HEART DISEASE	Published	
19412-5004CA	Canada	2603857	TREATMENT OF HEART DISEASE	Pending	
19412-5004US	United States of America	11/354637	TREATMENT OF HEART DISEASE	Published	
19412-5004JP	Japan	2010-165854	INJECTION SYSTEM	Published	
19412-5008US	United States of America	08/863882	TRANSPLANTS FOR MYOCARDIAL SCARS AND METHODS AND CELLULAR PREPARATIONS	Granted	6110459
19412-6001US	United States of America	08/333676	EMBRYONIC STEM CELLS CAPABLE OF DIFFERENTIATION INTO DESIRED CELL LINES	Granted	6432711